MA42196A - Particules de fumarate de diméthyle et leurs compositions pharmaceutiques - Google Patents
Particules de fumarate de diméthyle et leurs compositions pharmaceutiquesInfo
- Publication number
- MA42196A MA42196A MA042196A MA42196A MA42196A MA 42196 A MA42196 A MA 42196A MA 042196 A MA042196 A MA 042196A MA 42196 A MA42196 A MA 42196A MA 42196 A MA42196 A MA 42196A
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- dimethyl fumarate
- fumarate particles
- particles
- dimethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562181061P | 2015-06-17 | 2015-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42196A true MA42196A (fr) | 2018-04-25 |
Family
ID=56292916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042196A MA42196A (fr) | 2015-06-17 | 2016-06-15 | Particules de fumarate de diméthyle et leurs compositions pharmaceutiques |
Country Status (13)
Country | Link |
---|---|
US (2) | US11291642B2 (fr) |
EP (1) | EP3310341A1 (fr) |
JP (2) | JP2018517735A (fr) |
KR (1) | KR20180018711A (fr) |
CN (1) | CN107920997A (fr) |
AU (2) | AU2016279997B2 (fr) |
CA (1) | CA2989581A1 (fr) |
EA (1) | EA201890068A1 (fr) |
HK (1) | HK1254054A1 (fr) |
IL (1) | IL256296A (fr) |
MA (1) | MA42196A (fr) |
MX (1) | MX2017016509A (fr) |
WO (1) | WO2016205270A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3003237A1 (fr) * | 2015-10-28 | 2017-05-04 | Sun Pharmaceutical Industries Limited | Compositions pharmaceutiques de fumarate de dimethyle |
EP3413879A1 (fr) * | 2016-02-11 | 2018-12-19 | Biogen MA Inc. | Formulations pharmaceutiques de billes comprenant du diméthylfumarate |
AU2018346826B2 (en) * | 2017-10-02 | 2021-09-16 | Novartis Ag | Method for preparing a pharmaceutical product |
US11318682B2 (en) | 2018-04-06 | 2022-05-03 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3D) object printing based on build material permeability |
JP2022504333A (ja) * | 2018-10-05 | 2022-01-13 | アイエスピー インヴェストメンツ エルエルシー | 水溶性セルロースエーテルを含有する平滑な高固形分フィルムコーティング組成物、その調製方法およびその使用方法 |
TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
AU2020240108A1 (en) * | 2019-03-20 | 2021-11-11 | Lyndra Therapeutics, Inc. | Capsules and capsule coatings for gastric residence dosage forms |
US11590071B2 (en) * | 2021-07-06 | 2023-02-28 | King Abdulaziz University | Injectable drug delivery implant composition and method of use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20140099364A2 (en) * | 2004-10-08 | 2014-04-10 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
PT2997953T (pt) | 2006-01-18 | 2019-02-04 | Intec Pharma Ltd | Dispositivo oe entrega para ingestão oral oe um agente |
HUE030958T2 (en) * | 2008-04-18 | 2017-06-28 | Intec Pharma Ltd | Gastro-active drug delivery to carbidopa / levodopa |
PT2379063E (pt) * | 2009-01-09 | 2013-05-03 | Forward Pharma As | Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão |
JP2012514623A (ja) * | 2009-01-09 | 2012-06-28 | フォーワード・ファルマ・アクティーゼルスカブ | 1またはそれ以上のフマル酸エステルを含む医薬組成物 |
CN103649041A (zh) | 2011-06-08 | 2014-03-19 | 比奥根艾迪克Ma公司 | 制备高纯度和结晶的富马酸二甲酯的方法 |
WO2013076216A1 (fr) * | 2011-11-24 | 2013-05-30 | Synthon Bv | Libération contrôlée de particules comprenant du diméthylfumarate |
CN114146080A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
US20150079180A1 (en) | 2013-09-18 | 2015-03-19 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
IN2013MU03070A (fr) * | 2013-09-25 | 2015-07-17 | Glenmark Pharmaceuticals Ltd | |
EP3079663A1 (fr) | 2013-12-13 | 2016-10-19 | Biogen MA Inc. | Forme pharmaceutique à libération contrôlée pour administration une fois par jour de fumarate de diméthyle |
EP3501510B1 (fr) * | 2014-02-28 | 2020-07-01 | Banner Life Sciences LLC | Capsules entériques molles à libération contrôlée d'esters de fumarate |
-
2016
- 2016-06-15 MA MA042196A patent/MA42196A/fr unknown
- 2016-06-15 JP JP2017565133A patent/JP2018517735A/ja active Pending
- 2016-06-15 EP EP16733793.0A patent/EP3310341A1/fr not_active Withdrawn
- 2016-06-15 MX MX2017016509A patent/MX2017016509A/es unknown
- 2016-06-15 CA CA2989581A patent/CA2989581A1/fr active Pending
- 2016-06-15 AU AU2016279997A patent/AU2016279997B2/en not_active Ceased
- 2016-06-15 KR KR1020187001091A patent/KR20180018711A/ko not_active Application Discontinuation
- 2016-06-15 EA EA201890068A patent/EA201890068A1/ru unknown
- 2016-06-15 US US15/737,011 patent/US11291642B2/en active Active
- 2016-06-15 WO PCT/US2016/037486 patent/WO2016205270A1/fr active Application Filing
- 2016-06-15 CN CN201680047251.2A patent/CN107920997A/zh active Pending
-
2017
- 2017-12-13 IL IL256296A patent/IL256296A/en unknown
-
2018
- 2018-10-12 HK HK18113117.1A patent/HK1254054A1/zh unknown
-
2021
- 2021-11-12 JP JP2021184469A patent/JP2022042512A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200155A patent/AU2022200155A1/en not_active Abandoned
- 2022-02-22 US US17/677,204 patent/US20220362195A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US11291642B2 (en) | 2022-04-05 |
AU2016279997B2 (en) | 2021-10-21 |
IL256296A (en) | 2018-02-28 |
AU2016279997A1 (en) | 2018-01-18 |
MX2017016509A (es) | 2018-08-16 |
KR20180018711A (ko) | 2018-02-21 |
US20190070143A1 (en) | 2019-03-07 |
WO2016205270A8 (fr) | 2017-01-19 |
AU2022200155A1 (en) | 2022-02-10 |
JP2018517735A (ja) | 2018-07-05 |
US20220362195A1 (en) | 2022-11-17 |
EA201890068A1 (ru) | 2018-09-28 |
WO2016205270A1 (fr) | 2016-12-22 |
CN107920997A (zh) | 2018-04-17 |
HK1254054A1 (zh) | 2019-07-12 |
JP2022042512A (ja) | 2022-03-14 |
EP3310341A1 (fr) | 2018-04-25 |
CA2989581A1 (fr) | 2016-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL262495B (en) | History of isoquinolin-3-yl carboxamide and pharmaceutical preparations containing them | |
HK1259145A1 (zh) | 3-脫氧衍生物及其藥物組合物 | |
HK1251153A1 (zh) | 一種藥物組合物及其應用 | |
DK3529248T3 (da) | Farmaceutiske sammensætninger | |
MA42196A (fr) | Particules de fumarate de diméthyle et leurs compositions pharmaceutiques | |
MA50541A (fr) | Formulations pharmaceutiques | |
MA42303A (fr) | Formulations pharmaceutiques | |
MA41794A (fr) | Agents thérapeutiques modifiés et compositions associées | |
MA46867A (fr) | Formulations pharmaceutiques | |
MA45187A (fr) | Combinaisons pharmaceutiques | |
MA49837A (fr) | Compositions pharmaceutiques | |
PL3145508T3 (pl) | Nanocząstki klewidypiny i ich kompozycje farmaceutyczne | |
SG10202008700VA (en) | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
DK3280447T3 (da) | Farmaceutiske formuleringer | |
HK1245113A1 (zh) | 藥物組合物及其用途 | |
DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
DK3288933T3 (da) | Oxindolforbindelser og farmaceutiske sammensætninger deraf | |
PL3236938T3 (pl) | Doustne miejscowe wodne kompozycje farmaceutyczne flurbiprofenu i dekspantenolu | |
IL254711B (en) | History of diazepine-indole and medicinal preparations containing them | |
MA42552A (fr) | Compositions pharmaceutiques de flurbiprofène et de tramadol | |
MA43126A (fr) | Compositions pharmaceutiques de fumarate de diméthyle | |
MA49625A (fr) | Compositions pharmaceutiques | |
ZA201903341B (en) | Pharmaceutical compositions and uses thereof | |
EP3560492C0 (fr) | Composition de particules lipidiques et composition pharmaceutique | |
MA45339A (fr) | Dérivé de 3-désoxy et compositions pharmaceutiques associées |